Merkel Cell Carcinoma: An Update and Immunotherapy

Area of Science:

• Oncology
• Immunology
• Dermatology

Background:

• Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer with a 30% mortality rate, increasing in incidence.
• MCC is considered immunogenic, occurring more in immunosuppressed individuals.
• Causative factors include UV exposure and Merkel cell polyomavirus (MCPyV) integration, associated with ~80% of MCC cases.

Purpose of the Study:

• To explore the immunogenic nature of MCC.
• To investigate the role of MCPyV and immune checkpoints in MCC pathogenesis.
• To evaluate the potential of immunotherapy for MCC treatment.

Main Methods:

• Review of existing studies on MCC etiology and immunology.
• Analysis of MCPyV association with MCC.
• Examination of PD-1/PD-L1 expression in MCC tumors and tumor-infiltrating lymphocytes.

Main Results:

• MCC exhibits a high mortality rate and increasing incidence.
• MCPyV is a major factor in ~80% of MCC cases, with MCPyV-specific T cells present.
• PD-1 and PD-L1 expression observed in a subset of MCC, indicating an endogenous immune response.

Conclusions:

• MCC's immunogenic nature and association with MCPyV suggest a role for the immune system.
• PD-1/PD-L1 expression points to potential efficacy of immune checkpoint inhibitors (anti-PD-1/anti-PD-L1 therapies).
• Further research into immunotherapy is warranted for Merkel cell carcinoma treatment.